Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t... Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Mostrar más
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.219 | -22.4907749077 | 5.42 | 6.04 | 4.201 | 335387 | 5.11029184 | CS |
| 4 | -2.139 | -33.738170347 | 6.34 | 6.53 | 4.201 | 241240 | 5.23772347 | CS |
| 12 | -1.799 | -29.9833333333 | 6 | 8.74 | 4.201 | 232932 | 6.45497735 | CS |
| 26 | -7.269 | -63.3740191805 | 11.47 | 12.76 | 4.201 | 319456 | 8.26277712 | CS |
| 52 | -12.239 | -74.4464720195 | 16.44 | 19.5 | 4.201 | 265425 | 10.7203857 | CS |
| 156 | -5.299 | -55.7789473684 | 9.5 | 22.33 | 4.201 | 235115 | 11.00135553 | CS |
| 260 | -5.299 | -55.7789473684 | 9.5 | 22.33 | 4.201 | 235115 | 11.00135553 | CS |
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
